Skip to main content
Premium Trial:

Request an Annual Quote

Aussie Proteome-Analysis Facility, Lumicyte Partner In Proteomic Biomarker Discovery

NEW YORK, Nov. 19 (GenomeWeb News) - The Australian Proteome Analysis Facility will partner with LumiCyte to develop LCI's STS biochip platform technology and to accelerate proteomic biomarker discovery, the facility said today.

 

Under terms of the agreement, LCI will provide access to its STS biochip platform to support APAF's biomarker discovery-research efforts. Using mass-spectrometry techniques, APAF will provide a range of evaluation, validation and showcasing proteomic studies to characterize the performance of the STS platform.

 

APAF and LCI will apply collaboratively to the Australian government for funding to support the STS platform research.

 

Financial terms of the collaboration were not disclosed.

The Scan

Highly Similar

Researchers have uncovered bat viruses that are highly similar to SARS-CoV-2, according to Nature News.

Gain of Oversight

According to the Wall Street Journal, the Biden Administration is considering greater oversight of gain-of-function research.

Lasker for mRNA Vaccine Work

The Scientist reports that researchers whose work enabled the development of mRNA-based vaccines are among this year's Lasker Award winners

PLOS Papers on Causal Variant Mapping, Ancient Salmonella, ALK Fusion Test for NSCLC

In PLOS this week: MsCAVIAR approach to map causal variants, analysis of ancient Salmonella, and more.